Castration Resistant Prostate Cancer Clinical Trial
Official title:
A Phase II Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer
This study is to evaluate the benefits of investigational drug, NRX 194204 in slowing down/stopping/reversing progression of the castration resistant and taxane resistant prostate cancer.
Numerous studies in pre-clinical models and in human clinical trials have clearly established the potential for the use of rexinoids in the treatment and prevention of cancer. NRX 194204, a second generation rexinoid, is a highly potent and specific activator of RXRs (retinoid X receptors). Because NRX 194204 is significantly more selective for the RXRs relative to the RARs (retinoic acid receptors) than a first generation approved drug, it is associated with fewer adverse events in clinical use. This study seeks to investigate NRX 194204 monotherapy in patients with castration- and taxane- resistant prostate cancer. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01120470 -
OGX-427 in Castration Resistant Prostate Cancer Patients
|
Phase 2 | |
| Completed |
NCT02384382 -
A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)
|
Phase 2 | |
| Recruiting |
NCT02502994 -
Phase 1 Study of GEN0101 in Patients With Recurrence of CRPC
|
Phase 1 | |
| Not yet recruiting |
NCT05919329 -
Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy
|
Phase 4 | |
| Completed |
NCT01646684 -
Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer
|
Phase 1 | |
| Terminated |
NCT01522443 -
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
|
Phase 3 | |
| Completed |
NCT01637402 -
A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer
|
Phase 2 | |
| Completed |
NCT02833883 -
Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer
|
Phase 1 | |
| Completed |
NCT01605227 -
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
|
Phase 3 | |
| Completed |
NCT04580485 -
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT01995058 -
Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer
|
Phase 2 | |
| Completed |
NCT03473925 -
Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)
|
Phase 2 | |
| Withdrawn |
NCT05445882 -
N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer
|
Phase 2 |